Tele: 561.316.3330
Breaking Medical Device News

Wednesday, October 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR

Greg Bertenshaw, Ph.D., to has been promoted to the position of Chief Operating and Science Officer, of BioMarker Strategies, LLC. effective immediately. Dr. Bertenshaw, formerly Vice President, Research & Development, will continue to report directly to Jerry Parrott, President and Chief Executive Officer.

Dr. Bertenshaw joined BioMarker Strategies as Senior Scientist in December 2011 and was promoted to Director, Research & Development, in December 2012. Mr. Parrott joined BioMarker Strategies in October 2013 and promoted Dr. Bertenshaw to Vice President, Research & Development, less than three months later.

Since the end of 2012, Dr. Bertenshaw has been responsible for development of the Company’s core technologies, the SnapPath® Cancer Diagnostics System and PathMAP® Functional Signaling Profiles. He has also been responsible for working with DLA Piper to protect the Company’s intellectual property on a global basis, including patents and trademarks.

Mr. Parrott said, “All of the patents granted to BioMarker Strategies around the world have been granted since I joined BioMarker Strategies as CEO in October 2013. My personal responsibility for this achievement rests on one decision. That was the decision to promote Greg Bertenshaw to Vice President three months after joining the Company.”

“Greg is also Principal Investigator on all of the National Cancer Institute grants and contracts awarded to our Company since the beginning of 2013,” Mr. Parrott said. “This includes the $1.5 Phase II Small Business Innovation Research contract we announced in January 2020, which supports continued development of our PathMAP Immunotherapy test to predict response to PD-1/PDL1 targeted immune checkpoint inhibitors, for individual patients with non-small lung cancer.”

The $8.3 million in nondilutive funding that BioMarker Strategies has received from NCI has provided important validation for the Company’s proprietary ex vivo cancer diagnostics technology – and has also played a major role financially.

Prior to joining Human Genome Sciences, Dr. Bertenshaw served as Director, New Technology, with Correlogic Systems, Inc., from 2006-2011, and with Clearant Inc., from 2002-2006 as a Scientist and subsequently as Director of Science. Dr. Bertenshaw holds a Ph.D. in Biochemistry and Molecular Biology from Pennsylvania State University College of Medicine, and a B.S. in Biochemistry from the University of Manchester, Manchester, United Kingdom.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced...

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

By using this website you agree to accept Medical Device News Magazine Privacy Policy